Literature DB >> 16112543

Inspiratory muscle training in exercise-induced paradoxical vocal fold motion.

Barbara A Mathers-Schmidt1, L R Brilla.   

Abstract

The purpose of the study was to determine if inspiratory muscle training (IMT) would result in increased inspiratory muscle strength, reduced perception of exertional dyspnea, and improved measures of maximal exercise effort in an athlete with exercise-induced paradoxical vocal fold motion (PVFM). The participant, an 18-year-old woman, had a 2-year history of acute dyspnea with exertion during soccer games. Spirometry, transnasal flexible laryngoscopy, and patient history supported a PVFM diagnosis. The ABAB within-subject withdrawal design study comprised IMT treatment and withdrawal phases, each lasting 5 weeks. The participant trained 5 days per week, completing five sets of 12 breaths at 75% maximum inspiratory pressure (MIP) per session. Data consisted of MIP, exertional dyspnea ratings, and maximal exercise measures. IMT resulted in increased MIP and decreased dyspnea ratings across both treatment phases. No change in MIP or dyspnea ratings occurred in response to treatment withdrawal. The maximal exercise test revealed minimal changes across phases. At end of the study, the participant reported experiencing no PVFM symptoms when performing the outcome measurement tasks and when playing soccer. Transnasal flexible laryngoscopy, after strenuous exercise and during rapid breathing and phonation tasks, revealed normal laryngeal findings. The findings suggest that IMT may be a promising treatment approach for athletes with exercise-induced PVFM.

Entities:  

Mesh:

Year:  2005        PMID: 16112543     DOI: 10.1016/j.jvoice.2005.03.005

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  8 in total

1.  Inspiratory muscle training: a simple cost-effective treatment for inspiratory stridor.

Authors:  John Dickinson; Greg Whyte; Alison McConnell
Journal:  Br J Sports Med       Date:  2007-05-04       Impact factor: 13.800

2.  Systematic review of the effectiveness of non-pharmacological interventions used to treat adults with inducible laryngeal obstruction.

Authors:  Jemma Haines; Jacklyn Ann Smith; James Wingfield-Digby; Jenny King; Janelle Yorke; Stephen J Fowler
Journal:  BMJ Open Respir Res       Date:  2022-06

3.  Impact of yoga in a case of vocal cord dysfunction with dysautonomia.

Authors:  Rozina Wadhwania
Journal:  Int J Yoga       Date:  2017 Jan-Apr

4.  Severe Exercise-Induced Laryngeal Obstruction Treated With Supraglottoplasty.

Authors:  Astrid Sandnes; Magnus Hilland; Maria Vollsæter; Tiina Andersen; Ingvild Øvstebø Engesæter; Lorentz Sandvik; John-Helge Heimdal; Thomas Halvorsen; Geir Egil Eide; Ola Drange Røksund; Hege H Clemm
Journal:  Front Surg       Date:  2019-07-31

Review 5.  Exercise-induced laryngeal obstruction (EILO) in athletes: a narrative review by a subgroup of the IOC Consensus on 'acute respiratory illness in the athlete'.

Authors:  Hege Havstad Clemm; J Tod Olin; Cameron McIntosh; Martin Schwellnus; Nicola Sewry; James H Hull; Thomas Halvorsen
Journal:  Br J Sports Med       Date:  2022-02-22       Impact factor: 18.473

Review 6.  Larynx during exercise: the unexplored bottleneck of the airways.

Authors:  Ola Drange Røksund; John-Helge Heimdal; Jan Olofsson; Robert Christiaan Maat; Thomas Halvorsen
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-18       Impact factor: 2.503

7.  Exercise-induced laryngeal obstruction in athletes treated with inspiratory muscle training.

Authors:  Astrid Sandnes; Tiina Andersen; Hege Havstad Clemm; Magnus Hilland; Maria Vollsæter; John-Helge Heimdal; Geir Egil Eide; Thomas Halvorsen; Ola Drange Røksund
Journal:  BMJ Open Sport Exerc Med       Date:  2019-01-18

8.  Clinical responses following inspiratory muscle training in exercise-induced laryngeal obstruction.

Authors:  Astrid Sandnes; Tiina Andersen; Hege Havstad Clemm; Magnus Hilland; John-Helge Heimdal; Thomas Halvorsen; Ola Drange Røksund; Maria Vollsæter
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-12-26       Impact factor: 3.236

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.